Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

Positional therapy trains sleep apnea patients for long-term recovery

Positional therapy can be a long-lasting and effective treatment for patients with positional obstructive sleep apnea (OSA), according to research presented at the 2026 ATS International Conference.

20 May 2026

Early CPAP nonadherence does not predict long-term treatment failure

Many insurers stop covering continuous positive airway pressure or CPAP devices if patients don't use them regularly in the first 90 days.

20 May 2026

Researchers identity patients with exceptional tirzepatide response outcomes

Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally.

19 May 2026

Once-nightly oral pill helps control obstructive sleep apnea

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference.

18 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

AHA calls for lifelong brain health strategy to prevent cognitive decline

The AHA scientific statement calls for a life-course approach to brain health that integrates cognitive, emotional, behavioral, vascular, environmental, inflammatory, sleep, microbiome, and social factors. It highlights how early-life exposures, mental health, pollution, chronic inflammation, poor sleep, gut dysbiosis, and socioeconomic adversity may shape brain resilience and later-life cognitive decline.

29 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Advanced heart, kidney and metabolic disease linked to higher cancer risk

People with advanced heart, kidney and metabolic disease may face a higher risk of developing cancer, according to new research published today in the American Heart Association's peer-reviewed scientific journal Circulation: Population Health and Outcomes.

27 Apr 2026

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

Sleep apnea more common in former football players than previously recognized

New research led by investigators at Vanderbilt Health and the Football Players Health Study at Harvard University suggests that sleep apnea may be far more common - and more clinically significant - among former professional football players than previously recognized.

22 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

Semaglutide for weight loss was linked to a sharp drop in alcohol use in this case report

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month. The authors frame this as a promising but preliminary finding that adds to growing evidence on GLP-1 drugs and alcohol use, while also stressing that this was a single case and that better AUD screening in family medicine remains important.

2 Apr 2026

Sleep apnea raises risk of cardiovascular events and death

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that those living with obstructive sleep apnea (OSA) have a 71% higher risk of cardiovascular events (CVEs) or death from any cause (all-cause mortality) compared with those not living with OSA.

2 Apr 2026

More US adolescents are obese but fewer are trying to lose weight

The rising obesity rates in American adolescents, coupled with declining weight-loss efforts, signal urgent needs for targeted public health interventions.

18 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

Brain breathing mechanism linked to persistent high blood pressure

A brain mechanism may explain why approximately 40% of people with hypertension continue to have high blood pressure despite taking medication. The discovery reveals potential targets for new treatments.

16 Mar 2026

Japanese study evaluates sleep architecture and safety of common insomnia drugs

OSA is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep.

12 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

New study uncovers link between pediatric OSA and higher risk of viral infections

A five-year study has revealed that children with sleep apnea are twice as likely to contract the flu or COVID-19, regardless of their age or weight.

17 Feb 2026

Tirzepatide shows dual benefits in sleep apnea trial improving metabolism and reducing inflammation

Tirzepatide significantly improved cardiometabolic risk markers in adults with obesity and moderate to severe obstructive sleep apnea in the SURMOUNT-OSA phase 3 trials. Mediation analyses suggest both weight loss and reduced sleep-disordered breathing contributed to improvements in inflammation, insulin resistance, lipids, and blood pressure.

9 Feb 2026